NO20020771L - Peptidformulering med forlenget frigjöring - Google Patents
Peptidformulering med forlenget frigjöringInfo
- Publication number
- NO20020771L NO20020771L NO20020771A NO20020771A NO20020771L NO 20020771 L NO20020771 L NO 20020771L NO 20020771 A NO20020771 A NO 20020771A NO 20020771 A NO20020771 A NO 20020771A NO 20020771 L NO20020771 L NO 20020771L
- Authority
- NO
- Norway
- Prior art keywords
- sustained release
- extended release
- compound
- peptide formulation
- release peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
ig Det beskrives et kompleks med forlenget frigjøring, Forbindelse (I), som omfatter Forbindelse (A) som har formelen. eller et farmasøytisk akseptabelt salt derav, og en kopolymer som omfatter poly-(L)-melke-glykol-vinsyre (P(I)LGT), hvor aminogruppen av nevnte Forbindelse (A) er ionisk bundet til en karboksylgruppe av P(I)LGT. Det beskrives videre en frem-gangsmåte for fremstilling av nevnte kompleks med forlenget frigjøring. Videre beskrives en farmasøytisk blanding som omfatter nevnte kompleks med forlenget frigjøring og én eller flere farmasøytisk akseptable bærere.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14964999P | 1999-08-18 | 1999-08-18 | |
PCT/US2000/022464 WO2001012233A2 (en) | 1999-08-18 | 2000-08-16 | Sustained release formulation of a peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20020771D0 NO20020771D0 (no) | 2002-02-15 |
NO20020771L true NO20020771L (no) | 2002-04-15 |
Family
ID=22531239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020771A NO20020771L (no) | 1999-08-18 | 2002-02-15 | Peptidformulering med forlenget frigjöring |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1204429B1 (no) |
JP (2) | JP4303438B2 (no) |
KR (1) | KR20020031407A (no) |
CN (1) | CN1164334C (no) |
AR (1) | AR025307A1 (no) |
AT (2) | ATE322911T1 (no) |
AU (1) | AU767837B2 (no) |
CA (1) | CA2391333C (no) |
CZ (1) | CZ2002333A3 (no) |
DE (2) | DE60027334T2 (no) |
DK (1) | DK1204429T3 (no) |
ES (2) | ES2209948T3 (no) |
HK (1) | HK1043308B (no) |
HU (1) | HUP0203060A3 (no) |
IL (1) | IL147802A0 (no) |
MX (1) | MXPA02001699A (no) |
NO (1) | NO20020771L (no) |
NZ (2) | NZ517646A (no) |
PL (1) | PL354120A1 (no) |
PT (1) | PT1204429E (no) |
RU (1) | RU2237675C2 (no) |
WO (1) | WO2001012233A2 (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IES990700A2 (en) | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
AU2004200688B2 (en) * | 1999-08-18 | 2007-01-25 | Ipsen Pharma S.A.S. | Sustained release formulation of a peptide |
SI1594517T1 (sl) | 2003-01-28 | 2007-10-31 | Microbia Inc | Sestavki za zdravljenje gastrointestinalnih motenj |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
MY158342A (en) | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
ES2614080T3 (es) | 2005-05-17 | 2017-05-29 | Sarcode Bioscience Inc. | Composiciones y métodos para el tratamiento de trastornos oculares |
WO2007145956A2 (en) * | 2006-06-05 | 2007-12-21 | Novartis Ag | USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3797775A1 (en) | 2007-10-19 | 2021-03-31 | Novartis AG | Compositions and methods for treatment of diabetic retinopathy |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
AU2012250776B2 (en) | 2011-05-04 | 2017-06-15 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
CN104797574B (zh) | 2012-07-25 | 2019-11-22 | 原生质生物科学股份有限公司 | Lfa-1抑制剂及其多晶型物 |
EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
MY176976A (en) | 2013-10-10 | 2020-08-28 | Bausch Health Ireland Ltd | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
WO2017123634A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015587A2 (en) * | 1993-01-06 | 1994-07-21 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
ATE284413T1 (de) * | 1993-08-09 | 2004-12-15 | Sod Conseils Rech Applic | Therapeutische peptid derivate |
IE960308A1 (en) * | 1996-04-23 | 1997-11-05 | Kinerton Ltd | Sustained release ionic conjugate |
RU2165942C2 (ru) * | 1996-04-23 | 2001-04-27 | Кинертон Лимитид | Биоразрушаемый сложный полиэфир и способ его получения (варианты) |
AR020650A1 (es) * | 1998-08-10 | 2002-05-22 | Poly Med Inc | Polimeros fosforilados y conjugados de los mismos |
IES990700A2 (en) * | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
-
2000
- 2000-08-16 DE DE60027334T patent/DE60027334T2/de not_active Expired - Lifetime
- 2000-08-16 DK DK00954105T patent/DK1204429T3/da active
- 2000-08-16 RU RU2002106820A patent/RU2237675C2/ru not_active IP Right Cessation
- 2000-08-16 ES ES00954105T patent/ES2209948T3/es not_active Expired - Lifetime
- 2000-08-16 DE DE60006250T patent/DE60006250T2/de not_active Expired - Lifetime
- 2000-08-16 NZ NZ517646A patent/NZ517646A/en unknown
- 2000-08-16 WO PCT/US2000/022464 patent/WO2001012233A2/en not_active Application Discontinuation
- 2000-08-16 NZ NZ526127A patent/NZ526127A/en unknown
- 2000-08-16 EP EP00954105A patent/EP1204429B1/en not_active Expired - Lifetime
- 2000-08-16 CZ CZ2002333A patent/CZ2002333A3/cs unknown
- 2000-08-16 ES ES03076829T patent/ES2258204T3/es not_active Expired - Lifetime
- 2000-08-16 CA CA002391333A patent/CA2391333C/en not_active Expired - Fee Related
- 2000-08-16 PL PL00354120A patent/PL354120A1/xx not_active Application Discontinuation
- 2000-08-16 HU HU0203060A patent/HUP0203060A3/hu unknown
- 2000-08-16 AU AU66444/00A patent/AU767837B2/en not_active Ceased
- 2000-08-16 PT PT00954105T patent/PT1204429E/pt unknown
- 2000-08-16 AT AT03076829T patent/ATE322911T1/de not_active IP Right Cessation
- 2000-08-16 IL IL14780200A patent/IL147802A0/xx unknown
- 2000-08-16 MX MXPA02001699A patent/MXPA02001699A/es active IP Right Grant
- 2000-08-16 JP JP2001516576A patent/JP4303438B2/ja not_active Expired - Fee Related
- 2000-08-16 KR KR1020027001919A patent/KR20020031407A/ko not_active Application Discontinuation
- 2000-08-16 AT AT00954105T patent/ATE252915T1/de not_active IP Right Cessation
- 2000-08-16 CN CNB008114943A patent/CN1164334C/zh not_active Expired - Fee Related
- 2000-08-17 AR ARP000104253A patent/AR025307A1/es unknown
-
2002
- 2002-02-15 NO NO20020771A patent/NO20020771L/no unknown
- 2002-06-25 HK HK02104716.3A patent/HK1043308B/zh not_active IP Right Cessation
-
2005
- 2005-08-22 JP JP2005239282A patent/JP2006008701A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20020771L (no) | Peptidformulering med forlenget frigjöring | |
DK1086124T3 (da) | Nye cyclosporiner | |
CA2445276A1 (en) | Aripiprazole oral solution | |
NO20015226L (no) | Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament. | |
AU5681800A (en) | Quinoline derivatives as antibacterials | |
BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
DK0889875T3 (da) | Cycloproylalkansyrederivater | |
WO2000068229A3 (en) | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | |
BR0007589A (pt) | Inibidores da proliferação de células | |
RU2010116779A (ru) | Производное амида индазолакриловой кислоты | |
NO983464L (no) | Buffersystemer for stabilisering av farmas°ytiske preparater | |
WO2003086471A3 (en) | Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin | |
ATE253359T1 (de) | Antithrombotische mittel | |
PT880520E (pt) | Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase | |
DK1180094T3 (da) | Kondenserede polycykliske aminosyrer som farmaceutiske midler | |
NO980058L (no) | Opthalmiske preparater | |
HUP9702448A2 (hu) | Indolkarbonsavat tartalmazó, parenterálisan adható gyógyászati készítmény | |
WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
AU7470098A (en) | Antithrombotic agents | |
HK1041000A1 (en) | Novel pyrimidine derivatives and processes for thepreparation thereof. | |
CA2380902A1 (en) | Process to make a sustained release formulation | |
DE60008430D1 (de) | Verbindungen mit antithrombotischer wirkung | |
NO20001846L (no) | Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer | |
ATE268768T1 (de) | Antithrombosemittel | |
CA2245758A1 (en) | Benzo[c]quinolizine derivatives, their preparation and use as 5.alpha.-reductases inhibitors |